- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ONXX Market Currents
more »
-
Thursday 11:24 AM Onyx Pharmaceuticals (ONXX +4.7%) says that Bayer (BAYRY.PK) has submitted a New Drug Application to the FDA seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales. Separately, Bernstein initiates the shares with an Outperform rating.
Comment![Healthcare, On the Move]
- Tuesday 4:54 AM Bayer (BAYRY.PK) and Onyx Pharmaceuticals (ONXX) announce a Phase 3 trial of Nexavar tablets in patients with certain lung cancers did not meet its primary endpoint of improving overall survival. [Healthcare]
ONXX in Focus
more »
ONXX Related Articles
more »
ONXX News
more »
-
at CNBC.com (Wed, 4:52PM)
-
at CNBC.com (Tue, 5:04PM)
-
at CNBC.com (Tue, 9:13AM)
-
at CNBC.com (Tue, 8:11AM)
-
at CNBC.com (Jan 10, 2012)
ONXX Press Releases and Filings
more »
-
PR Newswire (Wed, 12:33PM)
-
PR Newswire (Tue, 2:30AM)
-
PR Newswire (May 16, 2012)
-
PR Newswire (May 2, 2012)
-
PR Newswire (Apr 30, 2012)
ONXX Latest Transcript
more »
ONXX Cramer
more »
-
Sun, Dec 6, 2009
-
Fri, Nov 6, 2009
-
Tue, Sep 22, 2009
ONXX Instablog posts
more »
ONXX vs. ETF Alternatives
Company Description
We are a biopharmaceutical company dedicated to developing innovative therapies that target the molecular mechanisms that cause cancer. Through our internal research programs and in conjunction with our collaborators, we are applying our expertise to develop and commercialize therapies designed... More
